drugset
drugset / Trial / NCT05818514

A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy Participants

NCT05818514 ↗

Phase 0 Completed 8 enrolled AstraZeneca
NaSequentialOpen-labelBasic science

Summary

The purpose of this study is to measure the regional distribution and binding of \[11C\]AZ14132516 to CCR9 in the abdomen using PET-CT examination in healthy participants. Study details include: The study duration will be up to 60 days. The IV radioligand \[11C\]AZ14132516 will be administered at PET-CT examination: Visit 2 for the pilot panel; Visit 2 and 3 in the main panel. There will be 2 study visits for the pilot panel and 3 study visits for the main panel.

Timeline

Start
2023-04-27
Primary completion
2023-07-11
Completion
2023-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject [11C]AZ14132516 Diagnostic / imaging agent 10 ug Intravenous

Indications

No indication recorded.